Sana Biotechnology will reduce its workforce by 29%, the Seattle-based cell and gene therapy company revealed in a SEC filing Tuesday.
- The company said it is increasing focus on its ex vivo cell therapy product candidates, resulting in a “strategic re-positioning” and delaying other projects.
- Sana previously cut 15% of its staff in November. The company employed about 500 people at the time. It also laid off employees earlier this year.
- Sana, which went public in 2021, said it will continue development of its manufacturing facility in Bothell, Wash.
- The company said it had $325.9 million in cash as of June 30, down from $434 million in the year-ago period. It reported a net loss of $114 million in its most recent second quarter.
